2027 General Election:
--d
--h
--m
--s
See Politics Coverage →
In Other News · United States · Business
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Source: CNBC
Summary
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.
Continue reading on CNBC →
You'll be taken to www.cnbc.com
← Back to In Other News
Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.
None
Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.
None
Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.
None
Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.
None
Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
None